Abstract
Aims: This study aimed to identify potential, non-invasive biomarkers for diagnosis and monitoring of the progress in multiple myeloma (MM) patients.Methods: MM patients and age-matched healthy controls (HC) were recruited in Discovery phase and Validation phase, respectively. MM patients were segregated into active group (AG) and responding group (RG). Serum samples were collected were conducted to non-targeted metabolomics analyses. Metabolites which were significantly changed (SCMs) among groups were identified in Discovery phase and was validated in Validation phase. The signaling pathways of these SCMs were enriched. The ability of SCMs to discriminate among groups in Validation phase was analyzed through receiver operating characteristic curve. The correlations between SCMs and clinical features, between SCMs and survival period of MM patients were analyzed.Results: Total of 23 SCMs were identified in AG compared with HC both in Discovery phase and Validation phase. Those SCMs were significantly enriched in arginine and proline metabolism and glycerophospholipid metabolism. 4 SCMs had the discriminatory ability between MM patients and healthy controls in Validation phase. Moreover, 12 SCMs had the ability to discriminate between the AG patients and RG patients in Validation phase. 10 out of 12 SCMs correlated with advanced features of MM. Moreover, 8 out of 12 SCMs had the negative impact on the survival of MM. 5′-Methylthioadenosine may be the only independent prognostic factor in survival period of MM.Conclusion: 10 SCMs identified in our study, which correlated with advanced features of MM, could be potential, novel, non-invasive biomarkers for active disease in MM.
Highlights
Multiple myeloma (MM) is a lethal plasma cell malignancy characterized by the amplification of clonal plasma cells in the bone marrow (Hanbali et al, 2017)
It accounts for 10% of hematologic malignancies worldwide, with clinical features consisting of hypercalcemia (C), renal failure (R), anemia (A), and bone lesions (B), which is known as CRAB symptom (Hanbali et al, 2017; Zhang et al, 2017)
A total of 75 subjects were enrolled in Validation phase
Summary
Multiple myeloma (MM) is a lethal plasma cell malignancy characterized by the amplification of clonal plasma cells in the bone marrow (Hanbali et al, 2017). It accounts for 10% of hematologic malignancies worldwide, with clinical features consisting of hypercalcemia (C), renal failure (R), anemia (A), and bone lesions (B), which is known as CRAB symptom (symptomatic MM or active MM) (Hanbali et al, 2017; Zhang et al, 2017). MM is incurable, and most of patients inevitably undergo disease progression or multiple relapses during the course. It is reported that the prognostic factors of MM include international staging system (ISS) stage or revised R-ISS staging, genetic aberrations and monoclonal protein (M protein) levels (Caltagirone et al, 2014; Kraj, 2014; Kuiper et al, 2015; Song et al, 2015; Tandon et al, 2017)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
